On behalf of Daiichi Sankyo, Inc. and AstraZeneca, we cordially invite you to join us for an informative, expert-led discussion.
This Program will cover:
- An FDA-approved therapy for adult patients with HER2+ unresectable or metastatic breast cancer after two or more prior anti-HER2-based regimens in the metastatic setting*
- Results from the Phase 2 clinical trial, DESTINY-Breast01 • Key safety considerations for ENHERTU
- Dosage and administration of ENHERTU®
Speaker: Yuan Yuan – Associate Professor in the Department of Medical Oncology and Therapeutic Research City of Hope Comprehensive Cancer Center in Duarte, California
RSVP by 7/7/21:
Joyce Lew – Mobile: 415.987.8862 email@example.com